Get started
Author

Ashley N. Davis

Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs
2019 · Susannah L. Hewitt, Ailin Bai, et al. · Science Translational Medicine · 317
The dorsal root ganglion in Friedreich’s ataxia
2009 · Arnulf H. Koeppen, Jennifer A. Morral, et al. · Acta Neuropathologica · 120
The cerebellar component of Friedreich’s ataxia
2011 · Arnulf H. Koeppen, Ashley N. Davis, et al. · Acta Neuropathologica · 94
Pathology and pathogenesis of sensory neuropathy in Friedreich’s ataxia
2010 · Jennifer A. Morral, Ashley N. Davis, et al. · Acta Neuropathologica · 87
Platelet Effects on Ovarian Cancer
2014 · Ashley N. Davis, Vahid Afshar-Kharghan, et al. · Seminars in Oncology · 64
Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer
2014 · Ju-Won Roh, Jie Huang, et al. · Clinical Cancer Research · 17
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
2015 · Rebecca A. Previs, Guillermo N. Armaiz-Pena, et al. · Molecular Cancer Therapeutics · 11
Data from Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
2023 · Rebecca A. Previs, Guillermo N. Armaiz-Pena, et al.
Supplementary Figure Legend from Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
2023 · Rebecca A. Previs, Guillermo N. Armaiz-Pena, et al.
Supplementary Figure 1 from Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
2023 · Rebecca A. Previs, Guillermo N. Armaiz-Pena, et al.
Supplementary Figure 1 from Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
2023 · Rebecca A. Previs, Guillermo N. Armaiz-Pena, et al.
Supplementary Figure Legend from Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
2023 · Rebecca A. Previs, Guillermo N. Armaiz-Pena, et al.
Data from Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
2023 · Rebecca A. Previs, Guillermo N. Armaiz-Pena, et al.
Data from Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer
2023 · Ju-Won Roh, Jie Huang, et al.
Data from Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer
2023 · Ju-Won Roh, Jie Huang, et al.
Supplementary Figures 1 - 3 from Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer
2023 · Ju-Won Roh, Jie Huang, et al.
Supplementary Figures 1 - 3 from Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer
2023 · Ju-Won Roh, Jie Huang, et al.
PDF
Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer
2021 · Ju-Won Roh, Jie Huang, et al. · Clinical Cancer Research
Abstract 2982: Macrophages modulate adaptive resistance to anti-angiogenic therapy
2014 · Heather J. Dalton, Sunila Pradeep, et al. · Cancer Research
Abstract 3340: Exploiting the non-overlapping dysregulation of Notch and PI3K/AKT signaling pathways as a guide for personalizing uterine cancer therapy
2014 · Rebecca A. Previs, Cristina Ivan, et al. · Cancer Research
Abstract 2995: Metronomic albumin-bound paclitaxel and topotecan has potent antitumor activity in ovarian cancer
2014 · Ashley N. Davis, Yvonne G. Lin-Liu, et al. · Cancer Research
Hitting the right mark: Nonoverlapping Notch and PI3K alterations in ovarian cancer
2014 · A.N. Davis, C. Ivan, et al. · Gynecologic Oncology
A dose a day keeps the cancer away: Metronomic albumin-bound paclitaxel and topotecan has potent antitumor activity in ovarian cancer
2014 · A.N. Davis, Y.G. Lin, et al. · Gynecologic Oncology
Works count: 25
Citation count: 710
H-index: 7
I10-index: 7
Year
Topic
Type